Biography:J. Keith Joung
J. Keith Joung is an American pathologist and molecular biologist who holds the Robert B. Colvin Endowed Chair in Pathology[1] at Massachusetts General Hospital and is Professor of Pathology at Harvard Medical School.[2] He is a leading figure in the field of genome editing and has pioneered the development of designer nucleases and sensitive off-target detection methods.[3]
Education
In 1987, Joung graduated from Harvard College with a bachelor's degree in biochemical sciences.[4] He received an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University.[5]
Career
Joung is most well known for his work in genome editing and has contributed to the development of designer nucleases through protein engineering and assays for off-target detection.[6][7][8] In the mid-2000s, his research was focused on creating zinc finger nuclease tools for biological research and gene therapy.[6] He was the leader and founder of the Zinc Finger Consortium and co-authored a study on Oligomerized Pool Engineering (OPEN), a publicly available strategy for rapidly constructing multi-finger arrays.[9][10]
More recently, he contributed to the development of TAL effector, TALENs, and the RNA-guided CRISPR/Cas9 system. In addition to demonstrating the use of the CRISPR/Cas9 system in vivo through the zebrafish model,[11] he pioneered the creation of tools such as GUIDE-seq and CIRCLE-seq to detect nuclease off-targets within the genome.[7][12] In 2016, his group became one of the first to report engineered high-fidelity CRISPR/Cas9 nucleases (HF1) with no detectable off-target effects.[13]
He is one of the scientific co-founders of Editas Medicine, along with Jennifer Doudna, Feng Zhang, George Church, and David Liu.[14] He is also a co-founder of Beam Therapeutics and Verve Therapeutics.[15][16] He received the Ho-Am Prize in Medicine in 2022 [17] and the American Society of Gene and Cell Therapy Outstanding Achievement Award in 2023, the society's highest honor.[18]
He has an h-index of 85 according to Semantic Scholar.[19]
References
- ↑ "Keith Joung, MD, PhD, was recognized as the inaugural incumbent of the Robert B. Colvin Endowed Chair in Patholog". https://www.massgeneral.org/pathology/news/joung-jan-2020.
- ↑ "Joung Laboratory - Massachusetts General Hospital, Boston, MA". massgeneral.org. http://www.massgeneral.org/pathology/research/researchlab.aspx?id=1271.
- ↑ Nair, Prashant (3 May 2016). "QnAs with Jennifer Doudna". Proceedings of the National Academy of Sciences 113 (18): 4884–4886. doi:10.1073/pnas.1605008113. PMID 27092008. Bibcode: 2016PNAS..113.4884N.
- ↑ "J Keith Joung MD PhD | Advisory Council | ASGCT - American Society of Gene & Cell Therapy | ASGCT - American Society of Gene & Cell Therapy". https://www.asgct.org/about/board-officers/j-keith-joung-md-phd.
- ↑ "Center for Computational and Integrative Biology". https://ccib.mgh.harvard.edu/joung#research.
- ↑ 6.0 6.1 Wade, Nicholas (28 December 2009). "In New Way to Edit DNA, Hope for Treating Disease". The New York Times. https://www.nytimes.com/2009/12/29/health/research/29zinc.html.
- ↑ 7.0 7.1 Tsai, Shengdar Q.; Zheng, Zongli; Nguyen, Nhu T.; Liebers, Matthew; Topkar, Ved V.; Thapar, Vishal; Wyvekens, Nicolas; Khayter, Cyd et al. (February 2015). "GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases". Nature Biotechnology 33 (2): 187–197. doi:10.1038/nbt.3117. PMID 25513782.
- "New method identifies genome-wide off-target cleavage sites of CRISPR-Cas nucleases". ScienceDaily (Press release). December 16, 2014.
- ↑ "CRISPR Researchers Develop Highly Sensitive Method for Identification of Off-Target Effects in Vivo". 12 September 2018. https://www.genomeweb.com/gene-silencinggene-editing/crispr-researchers-develop-highly-sensitive-method-identification-target#.XH8ifqeZNZ1.
- ↑ "The Zinc Finger Consortium | Consortium Members". zincfingers.org. http://www.zincfingers.org/consortium-members.htm.
- ↑ Maeder, Morgan L.; Thibodeau-Beganny, Stacey; Osiak, Anna; Wright, David A.; Anthony, Reshma M.; Eichtinger, Magdalena; Jiang, Tao; Foley, Jonathan E. et al. (July 2008). "Rapid 'Open-Source' Engineering of Customized Zinc-Finger Nucleases for Highly Efficient Gene Modification". Molecular Cell 31 (2): 294–301. doi:10.1016/j.molcel.2008.06.016. PMID 18657511.
- ↑ Hwang, Woong Y.; Fu, Yanfang; Reyon, Deepak; Maeder, Morgan L.; Tsai, Shengdar Q.; Sander, Jeffry D.; Peterson, Randall T.; Yeh, J.-R. Joanna et al. (March 2013). "Efficient genome editing in zebrafish using a CRISPR-Cas system". Nature Biotechnology 31 (3): 227–229. doi:10.1038/nbt.2501. PMID 23360964.
- ↑ Tsai, Shengdar Q.; Nguyen, Nhu T.; Malagon-Lopez, Jose; Topkar, Ved V.; Aryee, Martin J.; Joung, J. Keith (June 2017). "CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets". Nature Methods 14 (6): 607–614. doi:10.1038/nmeth.4278. PMID 28459458.
- ↑ Kleinstiver, Benjamin P.; Pattanayak, Vikram; Prew, Michelle S.; Tsai, Shengdar Q.; Nguyen, Nhu T.; Zheng, Zongli; Joung, J. Keith (January 2016). "High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects". Nature 529 (7587): 490–495. doi:10.1038/nature16526. PMID 26735016. Bibcode: 2016Natur.529..490K.
- ↑ "Editas Medicine to develop new class of genome editing therapeutics". 25 November 2013. https://mcgovern.mit.edu/2013/11/25/editas-medicine-to-develop-new-class-of-genome-editing-therapeutics/.
- ↑ "FOUNDERS AND INVENTORS". https://beamtx.com/about-us/.
- ↑ "About Us". https://www.vervetx.com/about-us/.
- ↑ 이인준 (31 May 2022). "32회 삼성호암상…오용근 포스텍 교수 등 6인 수상" (in Korean). https://newsis.com/view/?id=NISX20220531_0001892407.
- ↑ "Error: no
|title=specified when using {{Cite web}}". https://asgct.org/publications/news/april-2023/am23-awards-announcement. - ↑ "J. Joung". https://www.semanticscholar.org/author/J.-Joung/144322129?sort=pub-date.
 |  |
